圣诺生物：关于自愿披露维培那肽原料药获得上市申请批准通知书的公告

Core Viewpoint - The announcement from Shengnuo Biopharmaceuticals indicates that its wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the raw material drug, Weipena peptide [2] Group 1 - Shengnuo Biopharmaceuticals has a wholly-owned subsidiary named Chengdu Shengnuo Biopharmaceutical Co., Ltd. [2] - The company has received a marketing approval notification for Weipena peptide raw material from the National Medical Products Administration [2]